Form 4: ANAPTYSBIO CEO Daniel Faga Reports Stock Transactions

ANAPTYSBIO CEO Daniel Faga reported the acquisition of 26,838 shares from RSU vesting and the sale of 14,281 shares to cover tax obligations.

Summary

• Daniel Faga, President, CEO, and Director of ANAPTYSBIO, Inc., reported transactions involving the company's common stock.
• On January 7, 2026, Faga acquired 26,838 shares of common stock through the vesting and settlement of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share for no consideration, with 25% vesting annually commencing January 7, 2026.
• Following this acquisition, Faga's direct beneficial ownership was 493,625 shares.
• On January 8, 2026, Faga sold 14,281 shares at a price of $44.71 per share.
• This sale was explicitly stated to cover tax withholding obligations related to the RSU vesting and was not a discretionary transaction.
• After this sale, Faga's direct beneficial ownership stands at 479,344 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to RSU vesting and a subsequent 'sell to cover' tax obligation, which is a common practice and generally neutral in sentiment.

Positives

• The vesting of 26,838 restricted stock units (RSUs) indicates continued service and alignment of executive interests with shareholder value.
• The RSU vesting schedule, commencing January 7, 2026, with 25% vesting annually, provides a clear long-term incentive structure for the CEO.

Negatives

• Daniel Faga sold 14,281 shares of common stock at $44.71 per share, reducing his direct beneficial ownership.
• While the sale was for tax withholding, it still represents a reduction in the CEO's direct equity stake in the company.

Future Outlook

The remaining unvested RSUs will continue to vest at 25% annually from January 7, 2026, subject to Daniel Faga's continued provision of service to the Issuer.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This insider transaction report is specific to ANAPTYSBIO, Inc. and its CEO, Daniel Faga. It reflects routine compensation and tax-related share movements rather than broader industry trends.

Related Party Transactions

• The acquisition of 26,838 shares resulted from the vesting of Restricted Stock Units (RSUs) granted by the Issuer to Daniel Faga, an executive officer and director.

Stakeholder Impact

• Shareholders may observe a slight reduction in the CEO's direct beneficial ownership due to the 'sell to cover' transaction, though the non-discretionary nature of the sale mitigates concerns about executive confidence.
• The CEO, Daniel Faga, benefits from the vesting of RSUs as part of his compensation package, aligning his long-term interests with the company's performance.

Next Steps

• Future vesting of remaining restricted stock units (RSUs) for Daniel Faga, with 25% vesting annually from January 7, 2026.

Key Dates

Keywords

ANAPTYSBIO, ANAB, Daniel Faga, Form 4, insider trading, stock transaction, RSU, restricted stock unit, sell to cover